Document is current

Article History

Accepted: 20 June 2024

First Online: 29 July 2024

Competing interests

: S.Z.-S. has given a presentation for and received support for attending a meeting and/or travel from AbbVie, and has received a consultant fee from Siemens, outside the submitted work. P.C. received research grants by MSD and Intercept in the last 5 years unrelated to this work. J.M.P. reports having received consulting fees from Boehringer-Ingelheim, MSD and Novo Nordisk. He has received speaking fees from Gilead, Intercept and Novo Nordisk, and travel expenses from Gilead, Rubió, Pfizer, Astellas, MSD, CUBICIN and Novo Nordisk. He has received educational and research support from Madrigal, Gilead, Pfizer, Astellas, Accelerate, Novartis, Abbvie, ViiV and MSD, all outside the submitted work. D.I.-W. has no potential competing interests to disclose. Z.M.Y. acknowledges consulting fees from Intercept, Cymabay, Boehringer Ingelheim, Bristol Myers Squibb, GSK, Novo Nordisk, AstraZeneca, Siemens, Madridgal, Merck, Ipsen and Abbott, outside the submitted work. J.V.L. acknowledges grants and speaker fees from AbbVie, Echosens, Gilead Sciences, Moderna, MSD, Novo Nordisk and Roche Diagnostics to his institution, grants from Boehringer-Ingelheim, GSK and Madrigal to his institution, speaker fees from Janssen and ViiV, and consulting fees from AbbVie, Echosens, GSK Novavax and Pfizer, outside the submitted work.